Visiongain has published a new report entitled Geographic Atrophy Market Report 2025–2035 (Including Impact of U.S. Trade Tariffs): Forecasts by Type (Focal GA, Multifocal GA, Confluent GA), by Drugs (Pegcetacoplan (SYFOVRE), Avacincaptad Pegol (IZERVAY), Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Others), by Route of Administration (Intravitreal Route, Intravenous Route, Others), by Age Group (Below 60 Years, Above 60 Years, Above 70 Years), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global geographic atrophy market is estimated at US$7,056.3 million in 2025 and is projected to grow at a CAGR of 12.6% during the forecast period 2025-2035.

Impact of the U.S. Trade Tariffs on the Global Geographic Atrophy Market   

The introduction of U.S. trade tariffs is exerting a growing influence on the global market for geographic atrophy (GA) therapies. Biologics manufacturers, which depend on complex international supply chains, face rising challenges in securing sterile packaging, cold-chain logistics, and diagnostic devices. Tariff-related delays and cost increases in sourcing from exposed regions risk disrupting production schedules, complicating regulatory filings, and hindering coordinated launches across the U.S., Europe, and Asia-Pacific. For companies seeking to secure early market entry, such obstacles can erode competitive advantage.

In response, drug developers are rethinking their strategies. Many are diversifying supplier networks, shifting parts of production to tariff-neutral regions, and forming closer partnerships with U.S.-based contract manufacturing organisations. Stockpiling critical inputs is becoming more common, though this approach drives up inventory costs and locks in capital. Over the longer term, sustained tariffs are likely to favour companies with vertically integrated or domestic manufacturing operations, while smaller biotechs reliant on overseas suppliers could face mounting pressures, higher costs, and an increased need to merge or partner with larger players.

This evolving dynamic is poised to reshape the competitive structure of the GA market. While larger players may consolidate their positions, adoption in price-sensitive regions risks slowing, potentially delaying access to much-needed therapies for patients worldwide.

Growing Approval of Novel and Advanced Drugs

The year 2024 represents a turning point in the treatment of geographic atrophy (GA), following the U.S. FDA’s approval of pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) in 2023. By targeting complement proteins C3 and C5, these therapies introduced the first disease-modifying class of treatments for GA—shifting the standard of care away from supportive management alone. Uptake has been particularly strong across retina clinics in the U.S. and Europe, with growing demand among patients with bilateral GA and those experiencing rapid lesion progression. The success of these therapies underscores the recognition of complement inhibition as a breakthrough in slowing vision loss.

The pipeline is now broadening with promising new mechanisms of action. Annexon Biosciences’ ANX007, which targets C1q in the classical complement pathway, produced compelling Phase 2 ARCHER trial results, showing a 72% reduction in the risk of severe vision loss with monthly dosing. In parallel, oral candidates such as Danicopan from Alexion are under investigation, offering the potential advantage of systemic complement modulation combined with greater convenience for patients.

Taken together, these developments mark a decisive shift from symptomatic care to advanced immunomodulation. The therapeutic momentum not only strengthens disease control but also carries meaningful implications for improving long-term patient quality of life.

How will this Report Benefit you?

Visiongain’s 323-page report provides 130 tables and 190 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analysis for the geographic atrophy market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for geographic atrophy. Get financial analysis of the overall market and different segments including type, product and service, workflow, application, indication, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing geographic atrophy market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Development of Oral and Less Invasive Therapies

The treatment paradigm for geographic atrophy (GA) is shifting towards oral and less invasive solutions, designed to ease treatment burden and improve patient convenience. Several biopharmaceutical developers are progressing oral complement inhibitors and small-molecule modulators that could eventually replace or complement monthly intravitreal injections. Interim Phase 2 data, released in mid-2025, suggest that at least two oral agents are demonstrating non-inferiority on anatomical outcomes compared with injectable therapies. If validated, these treatments could drive better adherence, broaden market uptake, and improve quality of life—particularly for elderly patients who face challenges attending regular clinic visits.

Beyond oral options, innovations such as sustained-release depot implants and topical formulations are advancing through preclinical and early-stage trials. These delivery platforms have the potential to expand access by enabling treatment in outpatient clinics or even via tele-ophthalmology models, reducing the reliance on highly specialised retina centres. A move away from frequent injections towards more patient-friendly solutions could significantly transform the market, supporting broader adoption and extending care to underserved populations, especially in regions with limited access to advanced ophthalmic infrastructure.

Expanding Clinical Trial Pipeline for GA Treatments Is Propelling the Market Growth

The GA market is being reshaped by a rapidly growing clinical trial pipeline, reflecting both scientific momentum and commercial commitment. Once considered an underserved field, GA is now attracting substantial investment across diverse therapeutic approaches—including complement inhibition, gene therapy, and regenerative medicine—all aiming to slow or even reverse retinal degeneration.

In 2024, Boehringer Ingelheim advanced BI 771716, an investigational antibody fragment developed with CDR-Life, into Phase II trials following favourable Phase I safety results. The therapy, designed to penetrate retinal layers and act directly at the cellular level, underscores rising confidence in next-generation biologics and their potential to deliver precise and durable treatment outcomes. The breadth of ongoing development signals that GA is emerging as one of the most active frontiers in ophthalmology, with strong implications for both patient care and market growth.

Where are the Market Opportunities?

Growth Potential in Emerging Markets Including Asia Pacific and Latin America

Emerging markets are set to play a pivotal role in the expansion of geographic atrophy (GA) therapies, driven by demographic ageing and the steady improvement of healthcare infrastructure. Forecasts published in early 2025 suggest that by 2030, more than 30 million adults over the age of 60 in Asia Pacific could be at risk of GA, with the fastest growth anticipated in China, India, and Southeast Asia. In Latin America, urbanisation, rising life expectancy, and increased demand for eye care are prompting governments to expand ophthalmic services and enhance imaging capabilities in referral centres. These developments are creating fertile ground for commercial growth as patient populations expand and healthcare access improves.

Government-led programmes and nonprofit initiatives are further accelerating this momentum. In late 2024, Brazil launched a pilot project to extend OCT screening into community clinics, significantly improving detection rates of retinal diseases, including GA. Meanwhile, the International Agency for the Prevention of Blindness (IAPB) has stepped up efforts across India and Mexico, funding specialist training and running awareness campaigns for age-related macular degeneration. Together, these efforts are building diagnostic capacity, improving early detection, and raising disease awareness.

As these markets mature, they present clear opportunities for biopharma companies to establish a presence. However, success will depend on adapting pricing and reimbursement strategies to align with local economic conditions and ensuring therapies are accessible to both public and private health systems.

Competitive Landscape

The major players operating in the geographic atrophy market are Alkeus Pharmaceuticals, Annexon, Inc., Apellis Pharmaceuticals, Astellas Pharma, AstraZeneca, Aviceda Therapeutics, Bausch + Lomb, Belite Bio™ Inc., Boehringer Ingelheim, Cognition Therapeutics, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Johnson & Johnson, Santen Pharmaceutical, and Stealth BioTherapeutics Inc. Both well-established pharmaceutical companies and smaller biotech innovators are actively pursuing novel treatment approaches for Geographic Atrophy (GA). Although many of these players currently hold relatively small market positions, their collective progress represents a significant opportunity for disruption. As late-stage clinical trials advance and regulatory approvals expand, these companies are expected to broaden therapeutic options, intensify competition, and accelerate overall market growth.

Recent Developments

• 7 August 2025, Annexon, Inc. announced that the European Medicines Agency (EMA) selected vonaprument (formerly ANX007) for inclusion in its Product Development Coordinator (PDC) pilot program.
• 28 July 2025, Boehringer Ingelheim entered into a strategic partnership and licensing arrangement with Re-Vana Therapeutics, a US- and UK-based innovator specialising in ocular therapeutics and drug delivery systems. The collaboration seeks to advance the creation of pioneering extended-release treatments designed to address eye diseases.
• 24 July 2025, Annexon, Inc. reported full enrollment in the Phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company confirmed it is on schedule to release topline results in the second half of 2026. 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.